Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
|Videos|April 15, 2014
Sequencing Agents in Prostate Cancer
Author(s)Daniel P. Petrylak, MD
Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses sequencing agents in prostate cancer.
Advertisement
Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses sequencing agents in prostate cancer.
Clinical Pearls:
- Agents such as enzalutamide, abiraterone, and radium-223, are now FDA-approved and proven to improve survival
- Physicians sequence these agents based on approval parameters from the FDA, but this may not be the best way
- Physicians need to understand more about the biology and cross-resistance patterns of these agents and how to integrate rational combinations with limited toxicities in order to improve sequencing techniques
Advertisement
Related to this article
Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.
The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.
The first-in-class oral RIPTAC molecule JNJ-6143 reached a 75% overall response rate and significant declines in PSA in metastatic castration-resistant prostate cancer.
In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5